Y-mAbs Therapeutics CFO Kruse Resigns After Nine Years in the Role

Thursday, 14 March 2024, 13:08

Y-mAbs Therapeutics has announced that CFO Kruse will resign from his position after serving for nine years. The company is actively seeking a successor for the role. Kruse's departure marks a significant change in the financial leadership at Y-mAbs Therapeutics.

LivaRava Finance Meta Image — Y-mAbs Therapeutics CFO Kruse Resigns After Nine Years in the Role

Y-mAbs Therapeutics Announcement

Y-mAbs Therapeutics has confirmed the resignation of CFO Kruse after a long tenure of nine years. The company is in the process of finding a suitable replacement to fill the role.

Key Points:

CFO Resignation: CFO Kruse to step down from current role.
Successor Search: Y-mAbs actively seeking new CFO.

This change in leadership showcases a new era for Y-mAbs Therapeutics as they transition financial responsibilities.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.